173 related articles for article (PubMed ID: 32448790)
1. 10-Valent pneumococcal non-typeable
Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
[TBL] [Abstract][Full Text] [Related]
3. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
[TBL] [Abstract][Full Text] [Related]
4. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Morris PS
BMC Pediatr; 2021 Mar; 21(1):117. PubMed ID: 33685411
[TBL] [Abstract][Full Text] [Related]
5. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.
Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS
Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611
[TBL] [Abstract][Full Text] [Related]
6. Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal
Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Licciardi P; Skull S; Andrews R; Carapetis J; McDonnell J; Krause V; Morris PS
Vaccine X; 2021 Apr; 7():100086. PubMed ID: 33681756
[TBL] [Abstract][Full Text] [Related]
7. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
Leach AJ; Wigger C; Hare K; Hampton V; Beissbarth J; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
BMC Pediatr; 2015 Oct; 15():162. PubMed ID: 26482232
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
9. Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Skull SA; Oguoma VM; Chatfield M; Lehmann D; Binks MJ; Licciardi PV; Andrews R; Snelling T; Krause V; Carapetis J; Chang AB; Morris PS
Int J Pediatr Otorhinolaryngol; 2023 Dec; 175():111776. PubMed ID: 37951020
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.
Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; Brown NJ; McIntyre P; Smith-Vaughan H; Skull S; Balloch A; Andrews R; Carapetis J; McDonnell J; Krause V; Morris PS
BMJ Open; 2015 Jan; 5(1):e007247. PubMed ID: 25596202
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
[TBL] [Abstract][Full Text] [Related]
15. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
[No Abstract] [Full Text] [Related]
16. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
[TBL] [Abstract][Full Text] [Related]
17. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules.
Leach AJ; Wigger C; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
BMC Pediatr; 2014 Aug; 14():200. PubMed ID: 25109288
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
[TBL] [Abstract][Full Text] [Related]
20. Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland K; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Skull SA; Oguoma VM; Chatfield MD; Lehmann D; Brennan-Jones CG; Binks MJ; Licciardi PV; Andrews RM; Snelling T; Krause V; Carapetis J; Chang AB; Morris PS
PLoS Med; 2024 Jun; 21(6):e1004375. PubMed ID: 38829821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
